Japan pharmaceutical development-arkiv - Biosector Ltd.

An editorial infographic-style image, rendered in a highly detailed photorealistic illustration, shows multiple elevated railway tracks merging. One set of tracks, labeled with rusty signs for various local development milestones, curves into a main line labeled with a large overhead sign, 'GLOBAL DEVELOPMENT / MRCT (MULTI-REGIONAL CLINICAL TRIALS)'. Modern Japanese Shinkansen trains, including one with 'Phamaraxt' livery, travel on the main line. The scene is set in a daylight Yokohama cityscape, with skyscrapers and industrial buildings. Smaller rusty milestone signs date progress: 'DEC 2023 Phase I flexibility', 'OCT 2024 Rare-disease flexibility', 'JUN 2025 Clinical-trial reform', 'FEB 2026 One-stop service + PMDA', 'JUN 2026 Single IRB', and a final 'AUG 2026 Japan earlier in global development'. A main sign in the foreground left labels the converging tracks 'SEPARATE JAPANESE DEVELOPMENT'.

by Stefan Sandström

August 17, 2026

Clinical Trials in Japan: What Changed from December 2023 to August 2026

Japan changed important parts of its clinical development system in December 2023, when the Ministry of […]

0